Compleo Charging Solutions AG

  • ISIN: DE000A2QDNX9
  • Land: Deutschland

Nachricht vom 24.11.2021 | 10:51

Compleo Charging Solutions AG signs Letter of Intent for the delivery of 25,000 wallboxes per year

Compleo Charging Solutions AG / Key word(s): Letter of Intent/Incoming Orders
Compleo Charging Solutions AG signs Letter of Intent for the delivery of 25,000 wallboxes per year

24-Nov-2021 / 10:51 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Disclosure of inside information pursuant to Article 17 para. (1) of Regulation (EU) No. 596/2014 on Market Abuse as amended (Market Abuse Regulation - MAR)

Compleo Charging Solutions AG signs Letter of Intent for the delivery of 25,000 wallboxes per year

Dortmund, 24. November 2021 - Compleo Charging Solutions AG ("Compleo") has today entered into a non-binding Letter of Intent with a leading provider of innovative energy and storage solutions from Germany. The contractual partner is a wholly owned subsidiary of a leading German energy provider.

The Letter of Intent covers the annual supply of 25,000 Solo wallboxes from the 3rd quarter of 2022 for a period of three years. In this cooperation, it is envisaged that the Solo wallboxes will be technically tailored to the application needs in the field of photovoltaic and electricity storage systems for the home.

The letter of intent signed today has no impact on the forecast for the current fiscal year 2021.

Contact person and person responsible for the communication
IR contact
Compleo Charging Solutions AG
Sebastian Grabert, CFA
Head of Investor Relations
Phone: +49 231 534 923 874

24-Nov-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021